KAT2A and type 2 diabetes mellitus: Disruption of the GCN5-CITED2-PKA signalling module (such as that achieved by CITED2 depletion) also suppressed gluconeogenesis and ameliorated diabetes, suggesting that this module is a promising pharmacological target for treatment of obesity and type 2 diabetes.